ETHERNA
Live / Registered — Registered (as of 31 Dec 2024)
What this means for you
Registered since 31 Dec 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97728325
- Registration number
- 7634843
- Mark type
- Stylized text
- Filed
- 22 Dec 2022
- Published for opposition
- 02 Jan 2024
- Registered
- 31 Dec 2024
- Attorney of record
- Cheryl L. Burbach
Goods and services
- Class 001 — Chemicals: Biological preparations for scientific and research purposes for boosting cells in the immune system for improved therapies; biological preparations for scientific and research purposes, namely, a mRNA-based composition for enhancing immunities; biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents including complexes of these molecules for research purposes, for clinical research, clinical chemistry, clinical trials, scientific research, medical research, laboratory research, and for industrial use, namely, for use in the manufacture of pharmaceuticals
- Class 005 — Pharmaceuticals: Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; mRNA-based therapeutics and therapeutic agents for in prevention and treatment of viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; lipid nanoparticles for pharmaceutical, medical or diagnostic purposes for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for drug delivery sold as an integral component of drugs in the nature of pharmaceutical preparations for preventing and treating viruses, medical disorders, and diseases, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations, namely, messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
- Class 040 — Treatment of materials: Custom manufacture of pharmaceutical and medical preparations; custom manufacture of mRNA molecules; custom manufacture of mRNA molecules formulated in lipid nanoparticles; custom manufacture of mRNA for use in vaccines, cell therapy, gene editing, protein replacement, and antibodies; provision of information, advice and consultancy services relating to all of the aforesaid
- Class 042 — Scientific and technological services: Scientific research and development; pharmaceutical research and development services; medical research and development services; scientific, pharmaceutical, and medical research and development in the field of mRNA therapeutics; scientific, pharmaceutical, and medical research and development in the field of proprietary lipids and lipid nanoparticle formulations for the delivery of mRNA therapeutics for the treatment of various medical disorders, cancer, and infectious diseases
Owner
- eTheRNA immunotherapies NV, Niel, BE
- eTheRNA immunotherapies NV, Niel, BE
- eTheRNA immunotherapies NV, Niel, BE
Prosecution history
- 31 Dec 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 31 Dec 2024 — REGISTERED-PRINCIPAL REGISTER
- 10 Dec 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 10 Dec 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 22 Oct 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 16 Aug 2024 — USE AMENDMENT FILED
- 22 Oct 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 16 Aug 2024 — TEAS STATEMENT OF USE RECEIVED
- 13 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Aug 2024 — SOU EXTENSION 1 GRANTED
- 13 Aug 2024 — SOU EXTENSION 1 FILED
- 13 Aug 2024 — SOU TEAS EXTENSION RECEIVED
- 27 Feb 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Jan 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Jan 2024 — PUBLISHED FOR OPPOSITION